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Purpose: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. 
Patients who have frequent exacerbations are of particular concern. Practical exacerbation 
predictors are needed for these patients in the primary-care setting.
Patients and methods: Medical records of 130,547 asthma patients aged 12–80 years from 
the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 
1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most 
recent blood eosinophil count. Baseline variables predictive (P,0.05) of exacerbation in the 
outcome year were compared between patients who had two or more exacerbations and those who 
had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression 
models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency 
or inpatient) or acute oral corticosteroid (OCS) course.
Results: Blood eosinophil count .400/µL (versus #400/µL) increased the likelihood of two or 
more exacerbations .1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); 
P,0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing 
age (per year), female gender (versus male), being overweight or obese (versus normal body 
mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, 
gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal 
anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily 
controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds 
by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 
1.9-, or 3.1-fold, respectively (all P,0.05). Acute OCS use was the single best predictor of two 
or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 
[95% CI: 3.50, 4.01]; P,0.001), and three or more courses increased the odds by .25-fold 
(OR: 25.7 [95% CI: 23.9, 27.6]; P,0.001).
Conclusion: Blood eosinophil count and several other variables routinely available in patient 
records may be used to predict frequent asthma exacerbations.
Keywords: exacerbator, risk, multiple, hospitalization
Introduction
Acute, severe exacerbations of asthma are characterized by a rapid worsening of 
asthma symptoms, necessitating an urgent hospital visit and/or a course of systemic 
corticosteroids.1 Severe exacerbations are a well-recognized feature of asthma, yet they 
remain difficult to predict and thus prevent in many patients. Those who have multiple 
exacerbations in a year, sometimes termed frequent exacerbators2 or exacerbation-prone 
patients,3,4 are of particular concern, both for the patients themselves and for the added 
burden they place on health care systems.3,5
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The current recommendations for asthma management 
and prevention by the Global Initiative for Asthma (GINA) 
emphasize the importance of taking steps to reduce the 
patient’s exacerbation risk while also ensuring adequate 
symptom control.6 The recommendations review a number 
of specific exacerbation risk factors which form the basis of 
the strategies advised for reducing the patient’s exacerbation 
risk. Even so, more studies focused specifically on the risks 
for frequent exacerbations are needed. Whether or not they 
represent a distinct asthma phenotype,2,4 patients at risk for 
frequent exacerbations are in particular need of identification 
and targeted exacerbation risk management.3
A handful of cohort studies have investigated the specific 
risks for multiple exacerbations compared with patients who 
had, at most, one exacerbation in the same period. The fol-
lowing factors were significantly associated with frequent 
exacerbations: worse symptom control;2,7 greater number of 
exacerbations in the past year8,9 and exacerbations that were 
more severe (hospitalization, arrival by ambulance);9,10 being 
a smoker;2,11 having certain comorbidities, such as psycho-
social disorder,7,9 chronic sinusitis,9,10 recurrent respiratory 
infections,9 and gastroesophageal reflux disease;9 intolerance 
of nonsteroidal anti-inflammatory drugs (NSAIDs);10 greater 
use of inhaled corticosteroids (ICSs) and oral corticosteroids 
(OCSs);2,10 and having higher sputum2 or blood12 eosinophil 
counts, higher fractional exhaled nitric oxide (FeNO) values,2 
and poorer lung function.2,10
However, those studies were limited to specific patient 
populations (eg, emergency department attendees,7 adult non-
smokers,9,10 severe or difficult-to-treat asthma2,8,9), to ,100 
patients with multiple exacerbations,2,9–11 or to single indices 
(eg, blood eosinophil count12), and the definition of an exac-
erbation differed among studies. Characterization of patients 
at increased risk for frequent acute, severe exacerbations and 
identification of specific predictors are still needed for the 
general asthma population.
Furthermore, some of the reported exacerbation pre-
dictors, such as sputum eosinophil count and FeNO (both 
indicators of bronchial eosinophil activation2), may not be 
feasible across broad populations. Eosinophilic asthma is a 
common asthma phenotype,13 and elevated sputum or blood 
eosinophil counts have been associated with increased exac-
erbation risk,2,12,14–20 so assessment of eosinophil recruitment/
activation is important in the clinical evaluation of exacerba-
tion risk.21 However, not only is the assessment of bronchial 
eosinophilia impractical outside of tertiary care and research 
facilities, but there is also some evidence that systemic eosino-
philia may be a better predictor of severe exacerbations.16,21 
Thus, blood eosinophil count may be the more useful, as well 
as the more practical, clinical index of eosinophil recruitment 
and consequent exacerbation risk.
In this study, we investigated the value of blood eosino-
phil count and other routinely collected data – informa-
tion already available in the electronic medical records of 
most UK asthma patients or easily obtainable in general 
practice – for predicting multiple exacerbations in the 
next year. We hypothesized that data routinely collected 
during clinic visits may be used to identify asthma patients at 
significant risk for two or more exacerbations. By identifying 
specific risk factors and determining the predictive value of 
each within a multivariable model, our goal was to generate 
a weighted list of exacerbation predictors that would enable 
the physician to design an individualized management plan 
aimed at decreasing the patient’s exacerbation risk.
Patients and methods
study patients
We conducted a historical study of UK asthma patients treated 
in clinical practice, using data obtained from two large, anony-
mized patient databases: the Optimum Patient Care Research 
Database (OPCRD; http://www.optimumpatientcare.org) and 
Clinical Practice Research Datalink (CPRD; http://www.cprd.
com). Research use of the OPCRD was performed in compli-
ance with all applicable local and international laws and regula-
tions, including The International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human 
Use E6 guidelines for Good Clinical Practices. Research 
use of CPRD was approved by the UK National Information 
 Governance Board Ethics and Confidentiality Committee.
Data were examined for the period between August 1990 
and February 2013. Figure 1 summarizes the patient selection 
process. The final study group consisted of patients with a 
physician-recorded diagnosis of asthma but no other chronic 
respiratory disease, at least one valid blood eosinophil count 
(see the following paragraph), 1 full year of data on each 
side of the index blood eosinophil count, and aged between 
12 years and 80 years at the index date.
A valid blood eosinophil count constituted a numeri-
cal value recorded as, or able to be converted to, cells/µL. 
To avoid extreme outliers, patients with blood eosinophil 
counts .5,000/µL were excluded. When a patient had mul-
tiple valid blood eosinophil counts, the most recent count 
which allowed the collection of 1 full year of data before 
and after was selected as the index count.
Because hospital attendances and admissions tend to be 
underreported in these clinical practice databases, we also 
examined a subset of the study group for whom Hospital 
Episode Statistics (HES) data were available from the UK 
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Asthma diagnosis
n=406,474
Potential patients
n=595,658
No other
chronic resp disease
n=343,927
Valid blood
eosinophil count
n=220,960
Complete baseline
and outcome years
n=160,349
Excluded: <12 or
>80 years of age
n=29,802
Excluded: incomplete
baseline/outcome data
n=60,611
Excluded: missing or
invalid eosinophil count
n=122,967
Excluded: other
chronic resp disease
n=62,547
Excluded:
no asthma diagnosis
n=189,184
Age 12–80 years
n=130,547
Figure 1 cOnsOrT diagram of the patient selection process.
Abbreviation: resp, respiratory.
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National Health Service regarding inpatient admissions 
for asthma during the study period. (Further details of the 
full study group and the HES subset are provided in the 
 Supplementary materials).
study design
Our main objective was to identify and weight the routine clini-
cal indices that were predictive of multiple (2+) severe asthma 
exacerbations in the next year. To that end, we examined the 
medical record of each study patient for the year before (base-
line) and the year after (outcome) the date of the index blood 
eosinophil count. The baseline year was used to characterize the 
study population and identify variables that may be predictive 
of multiple exacerbations in the outcome year (Figure S1).
Outcomes and variables
The primary outcome of interest was the occurrence of 
acute, severe exacerbation (hereafter, simply called an 
Journal of Asthma and Allergy 2016:9
Table 1 Key baseline variables examined as predictors of multiple 
exacerbations
Variable Description
Age in years
gender Male or female
BMi in kg/m2; also categorized as underweight 
(,18.5), normal (18.5–24.9), overweight 
(25–29.9), or obese ($30)
smoking status nonsmoker, smoker, or ex-smoker
% predicted PeF PeF, expressed as percentage of 
predicted normal
Blood eosinophil count Actual value (cells/µl); also categorized 
as #400/µl or .400/µl
comorbidities Anaphylaxis (history), anxiety/depression, 
diabetes (type i or ii), eczema, gerD, 
heart failure, ischemic heart disease, 
psoriasis, rhinitis
comedications Prescription for acetaminophen or 
nsAiDs
Treatment stepa
 step 0 no treatment
 step 1 inhaled sABA as needed
 step 2 Add ics or lTrA
 step 3 Add lABA to ics or use high-dose ics 
($400 µg/day FP equivalent)
 step 4 Add lTrA/Theo to [ics + lABA] or add 
lABA/lTrA/Theo to high-dose ics
 step 5 Add Ocs
Average sABA dosage in µg/day, salbutamol equivalents 
(explained in text)
Average ics dosage in µg/day, FP equivalents  
(explained in text)
gP consults for lrTi consultations that resulted in antibiotic 
prescription (included to capture asthma 
events that may have been misclassified 
as lrTi)
Acute Ocs courses number of acute courses
hospital attendance/ 
admission
Any asthma-relatedb A&e, inpatient, or 
outpatient attendance/admission
exacerbations Occurrence of asthma-relatedb hospital 
A&e attendance, inpatient admission, or 
acute Ocs course
Notes: aBased on British Thoracic society recommendations (2011) for adults and 
children .12 years;22 bany with a lower respiratory code (Asthma or lrTi code).
Abbreviations: A&e, Accident and emergency department; BMi, body mass 
index; FP, fluticasone propionate; GERD, gastroesophageal reflux disease; GP, 
general practitioner; ics, inhaled corticosteroid; lABA, long-acting β2 agonist; 
lrTi, lower respiratory tract infection; lTrA, leukotriene receptor antagonist; 
NSAIDs, nonsteroidal anti-inflammatory drugs; OCS, oral corticosteroid; PEF, peak 
expiratory flow; SABA, short-acting β2 agonist; Theo, theophylline.
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exacerbation), as defined by the American Thoracic Society 
and European Respiratory Society1: asthma-related hospi-
tal attendance/admission (either Accident and Emergency 
department [A&E] or inpatient) or acute OCS course. Any 
such events within a 2-week window were counted as a single 
exacerbation.
In the HES subset, the outcome measure was the 
occurrence of hospital inpatient admission for asthma as 
recorded in the HES database (hereafter, simply called 
hospitalization).
The key baseline variables examined are summarized in 
Table 1; a complete list is provided in Table S1. Comorbid 
rhinitis (diagnosis of rhinitis at any time or prescription 
for rhinitis nasal spray during baseline year) was used as 
a proxy for atopy. The variable “treatment step” was based 
on the British Thoracic Society and Scottish Intercollegiate 
Guidelines Network (BTS-SIGN) recommendations for 
asthma in adults and children .12 years of age that were 
current at the time of data extraction.22 All short-acting β
2
 
agonist (SABA) dosages are reported as salbutamol equiva-
lents: terbutaline dosages were divided by 2.5 to yield the 
salbutamol-equivalent dosage. All ICS dosages are reported 
as fluticasone propionate (FP) equivalents: large-particle 
beclomethasone dipropionate (BDP) and budesonide dos-
ages were divided by 2 to yield the FP-equivalent dosage; 
extrafine-particle BDP and ciclesonide dosages were consid-
ered equivalent to FP dosages for this study. (Further details 
of the study design and variables examined are provided in 
the Supplementary materials).
statistical analysis
All analyses were conducted using SPSS Statistics version 21 
(IBM Corp, Armonk, NY, USA), SAS version 9.3 (SAS Insti-
tute Inc., Cary, NC, USA), and Microsoft Excel 2013 (Microsoft 
Corp, Redmond, WA, USA). We defined statistically significant 
results as P,0.05. Normally distributed data are reported as 
means with their standard deviations; data not normally dis-
tributed are reported as medians with their interquartile ranges 
(defined by their 25th and 75th percentiles). Odds ratios (ORs) 
are reported with their 95% confidence intervals (CIs).
Because some patients may have, at most, one exacerba-
tion in a year while others may have multiple, we compared 
patients who had no exacerbations or only one with those who 
had two or more (0/1 versus 2+ exacerbations). After gener-
ating descriptive statistics, correlations between potentially 
confounding baseline variables were assessed using Spear-
man correlation coefficients. Relationships with rank correla-
tion coefficients .0.30 were considered, in conjunction with 
clinical interpretation, to identify pairs of variables that may 
present collinearity issues at the modeling stage.
We began with univariable logistic regression mod-
els to identify baseline variables that were predictive of 
multiple exacerbations in the outcome year. The dichoto-
mous variable (0/1 versus 2+ exacerbations) was used as 
the dependent variable, with each baseline measure as an 
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Table 2 Key baseline patient characteristics: demographic and 
clinical indices
Variable N (%)a
Total patients 130,547 (100)
Age (years), mean (sD) 48.8 (17.4)
gender, female 86,039 (65.9)
BMi (kg/m2), mean (sD) 28.5 (6.5)
 Underweight 3,934 (3.2)
 normal 36,394 (29.6)
 Overweight 33,446 (27.2)
 Obese 49,108 (40.0)
smoking status
 nonsmoker 72,552 (55.7)
 smoker 24,443 (18.8)
 ex-smoker 33,253 (25.5)
% predicted PeF 105,515 (80.8)b
 Mean (sD) 83.9 (20.0)
Blood eosinophils (/µl), median (iQr) 200 (120, 350)
 .400 20,999 (16.1)
comorbidities
 Anaphylaxis, history 735 (0.6)
 Anxiety/depression 51,047 (39.1)
 Diabetes 32,433 (24.8)
 eczema 42,166 (32.3)
 gerD 19,114 (14.6)
 heart failure 4,172 (3.2)
 ischemic heart disease 7,815 (6.0)
 Psoriasis 6,133 (4.7)
 rhinitis 57,655 (44.2)
comedications, prescription for
 Acetaminophen 42,512 (32.6)
 nsAiDs 44,411 (34.0)
Notes: aexcept where noted; bonly 80.8% of patients had PeF data.
Abbreviations: BMI, body mass index; GERD, gastroesophageal reflux disease; 
IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs; PEF, peak 
expiratory flow, expressed as percentage of predicted normal; SD, standard deviation.
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explanatory variable. The baseline variables that showed a 
significant association with two or more exacerbations in the 
outcome year were entered into a multivariable model, which 
was stepwise reduced to produce a final list of noncollinear 
predictors of two or more exacerbations.
With the clinically relevant variables that were found to 
be collinear, we repeated the multivariable model, substitut-
ing the second variable of the pair for the first (eg, average 
daily SABA dosage for treatment step). Those results are 
reported separately. As not all patients had recorded base-
line values for peak expiratory flow (PEF), we repeated the 
analyses for the subset of patients with PEF data (excluding 
the patients missing PEF data) in order to determine the value 
of PEF for predicting multiple exacerbations. Those results 
are also reported separately.
In the HES subset, separate uni- and multivariable analy-
ses were conducted to identify baseline variables that were 
predictive of at least one hospitalization, using 0 versus 1+ as 
the dependent dichotomous variable. With regard to inpatient 
admissions for asthma during the baseline year, the results from 
the HES database and CPRD were recorded and analyzed sepa-
rately. However, in the final multivariable model for this subset, 
only inpatient admissions recorded in CPRD were used so that 
the ORs reflect the likelihood of hospital inpatient admission 
for asthma (as recorded in the HES system) using data from 
primary-care medical records (as recorded in CPRD).
Results
Baseline characteristics
Of 343,927 patients identified with asthma and no other chronic 
respiratory diseases, 220,960 patients had valid blood eosino-
phil counts recorded during the study period, and 130,547 
patients met the full study criteria (Figure 1). Key baseline 
characteristics are summarized in Tables 2 and 3; complete 
baseline data are provided in Tables S2 and S3. Mean age 
was 49 years, 66% of patients were female, 67% were either 
overweight (27%) or obese (40%), 44% were current (19%) or 
former (25%) smokers, and 44% had comorbid rhinitis. Mean 
PEF was 84% of predicted normal. The median blood eosino-
phil count was 200/µL; 16% of patients had a count .400/µL. 
Most patients were being managed at treatment step 2 (41%) 
or above (37%). Asthma-related A&E attendance or inpatient 
admission was reported in 0.6% of patients, and 19% of 
patients had one or more acute OCS courses.
exacerbation rates
Approximately 7% of patients had two or more exacerba-
tions in either their baseline (6.9%) or outcome (6.5%) year. 
Of the 9,009 patients who had two or more  exacerbations 
 during their baseline year, 3,681 (41%) patients had 
two or more exacerbations the following year. Of the 
121,538 patients who had no exacerbation or only one exac-
erbation in their baseline year, 4,748 (4%) patients had two 
or more exacerbations the following year (Table S3).
exacerbation predictors
The variables that were predictive (P,0.05) of two or more 
exacerbations in the full multivariable model are shown 
in Figure 2, along with their ORs, 95% CI, and P-values. 
( Univariable results are provided in Tables S4 and S5.) 
Overall, the likelihood of two or more exacerbations in the 
outcome year was highest in patients prescribed one or more 
acute OCS courses in the baseline year (Figure 2B). Of the 
demographic and clinical variables, having a blood eosinophil 
count .400/µL was the strongest predictor of two or more 
exacerbations (Figure 2A).
Journal of Asthma and Allergy 2016:9
Table 3 Key baseline patient characteristics: asthma treatment 
and control
Variable N (%)a
Treatment step
 0 13,654 (10.5)
 1 14,951 (11.5)
 2 53,964 (41.3)
 3 17,655 (13.5)
 4 29,243 (22.4)
 5 1,080 (0.8)
Average sABA dosage (µg/day) (salbutamol equivalent)
 Median (iQr) 164.4 (55, 384)
 0 25,371 (19.4)
 1–200 44,780 (34.3)
 201–400 29,778 (22.8)
 .400 30,618 (23.5)
Average ics dosage (µg/day) (FP equivalent)
 Median (iQr) 219.2 (55, 570)
 0 29,222 (22.4)
 1–200 29,198 (22.4)
 201–400 26,045 (20.0)
 401–800 24,440 (18.7)
 .800 21,642 (16.6)
gP consults for lrTi
 Median (iQr) 0 (0, 0)
 0 109,725 (84.1)
 1 15,508 (11.9)
 2+ 5,314 (4.1%)
Acute Ocs courses
 Median (iQr) 0 (0, 0)
 0 105,963 (81.2)
 1 14,214 (10.9)
 2 4,901 (3.8)
 3+ 5,469 (4.2)
hospital attendance/admission, at least one asthma-related
 A&e 333 (0.3)
 inpatient 455 (0.3)
 Outpatient 4,644 (3.6)
exacerbations
 0/1 121,538 (93.1)
 2+ 9,009 (6.9)
Notes: aexcept where noted.
Abbreviations: A&E, accident and emergency department; FP, fluticasone 
propionate; gP, general practitioner; ics, inhaled corticosteroid; iQr, interquartile 
range; lrTi, lower respiratory tract infection; Ocs, oral corticosteroid; sABA, 
short-acting β2 agonist.
Treatment step and average daily SABA and ICS dosages 
were found to be collinear, so only treatment step was used 
in the main multivariable model. When SABA or ICS dosage 
was used in place of treatment step (Figure 2C), average daily 
SABA and ICS dosages significantly influenced the likelihood 
of two or more exacerbations in a bidirectional pattern: com-
pared with no usage, low-to-moderate dosages (1–400 µg/day) 
significantly decreased the odds, and high dosages (.400 µg/
day SABA [salbutamol equivalent] and .800 µg/day ICS [FP 
equivalent]) significantly increased the odds of having two or 
more exacerbations in the next year. This pattern is consistent 
with that of treatment step (Figure 2B): compared with patients 
at step 2 (daily controller medication), those on no treatment 
(step 0) or only SABA as needed (step 1) were significantly 
more likely to have two or more exacerbations, as were those 
prescribed more intensive controller regimens (steps 3–5).
In the multivariable model that excluded the patients with 
no baseline PEF data, the likelihood of having two or more 
exacerbations in the next year decreased a small but signifi-
cant amount for every 1% increase in percent predicted PEF 
(OR: 0.990 [95% CI: 0.989, 0.992]; P,0.001). The results 
for this dataset were otherwise comparable with those of the 
full study population (data available upon request).
hospitalization predictors
The HES subset comprised 47,718 patients (37% of the full 
study population). Patient characteristics were similar to 
those of the full study group, except for inpatient admissions 
for asthma, which, as expected, were higher in the HES subset 
(1.2%) than in the full study group (0.3%), thus validating the 
inclusion of the HES subset. (Baseline data for these patients 
are provided in Tables S6 and S7, and univariable results in 
Tables S8 and S9).
The variables that were predictive (P,0.05) of at least 
one hospitalization for asthma in the next year are shown in 
Figure 3. Of note, hospitalization for asthma in the baseline 
year (as documented in the patient’s primary-care record) 
was the best predictor of hospitalization for asthma in the 
outcome year (as documented in the HES system). That is, 
even though the clinical practice database missed 76% of 
the HES inpatient admissions for asthma (Table S7), these 
primary-care data were still strongly predictive of hospital-
ization for asthma in the next year.
Discussion
This study was designed to investigate the specific compo-
nents that contribute to a patient’s risk for frequent exac-
erbations of asthma, using data found in routine medical 
records. Our multivariable analyses yielded .20 different 
exacerbation predictors, all of which are either readily 
available in UK patients’ electronic medical records (eg, 
age, gender, medications prescribed) or easily obtained 
in general practice (eg, body mass index [BMI], blood 
eosinophil count, percent predicted PEF). Not only does 
this list complement and expand upon the current GINA 
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Odds ratio (95% CI) P-valueA
Odds ratios (95% CI) 
1.007 (1.005, 1.008)
1.21 (1.14, 1.28) 
1.08 (1.01, 1.16)
1.17 (1.09, 1.24)
1.14 (1.06, 1.22) 
0.93 (0.88, 0.99)
1.48 (1.39, 1.58)
1.09 (1.04, 1.15)
1.11 (1.05, 1.17) 
1.08 (1.03, 1.14) 
1.12 (1.05, 1.20)
1.10 (1.04, 1.16)
1.23 (1.17, 1.30)
<0.001
<0.001
0.028
<0.001
<0.001
0.024
<0.001
0.001
<0.001
0.003
0.001
<0.001
<0.001
1.61.0
Decreasing likelihood Increasing likelihood of 2+ exacerbations
0.8
Gender, female versus male
Age, per year increase
Overweight versus normal BMI
Obese versus normal BMI
Smoker versus nonsmoker
Ex-smoker versus nonsmoker
Blood eosin >400/µL versus ≤400/µL
Anxiety/depression
Diabetes (type I or II)
Eczema
GERD
Rhinitis
Acetaminophen script*
Treatment step*
        versus step 2
0 1.58 (1.42, 1.76)
1.18 (1.06, 1.30)
1.27 (1.17, 1.38)
1.88 (1.77, 2.00)
3.12 (2.64, 3.68)
1.18 (1.10, 1.26)
1.28 (1.17, 1.40)
1.19 (1.08, 1.31)
3.75 (3.50, 4.01)
7.33 (6.74, 7.97)
25.7 (23.9, 27.6)
<0.001
0.002
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
12.83.20.8 1.0
1
1
2+
Outpatient, 1+
1
2
3+
GP consults for LRTI
Odds ratio (95% CI)
B
P-value
Odds ratios (95% CI) 
Hospital, asthma†
Acute OCS courses
3
4
5
Figure 2 (Continued )
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Treatment step versus step 1 or 2
Average ICS dosage, µg/day (FP equiv) versus 0
GP consults for LRTI
Acute OCS courses
Hospital, asthma 1+ (in clinic records)†
Odds ratio (95% CI) P-value
Outpatient 1.96 (1.48, 2.62) <0.001
3+ 3.73 (2.85, 4.91) <0.001
2 3.42 (2.56, 4.56) <0.001
1 2.02 (1.60, 2.56) <0.001
2+ 1.22 (0.89, 1.67) 0.215
>800 0.96 (0.67, 1.37) 0.819
401–800 0.86 (0.61, 1.21) 0.391
201–400 0.62 (0.44, 0.89) 0.009
1–200 0.77 (0.55, 1.08) 0.133
4 or 5 1.63 (1.29, 2.05) <0.001
0 1.69 (1.18, 2.41) 0.004
Ischemic heart disease 1.64 (1.23, 2.18) <0.001
3 1.03 (0.77, 1.39) 0.826
1 1.53 (1.24, 1.89) <0.001
Inpatient 5.86 (3.45, 9.95) <0.001
Diabetes (type I or II) 1.53 (1.28, 1.82) <0.001
Anxiety/depression 1.26 (1.07, 1.50) 0.006
Blood eosin >400/µL versus ≤400/µL 1.22 (0.99, 1.50) 0.062
Ex-smoker versus nonsmoker 0.89 (0.72, 1.09) 0.243
Smoker versus nonsmoker 1.23 (0.99, 1.52) 0.061
Anaphylaxis, history 1.90 (0.92, 3.94) 0.084
0.25 0.5 1 2
Odds ratios (95% CI)
4 8
Figure 3 hes subset: odds of at least one inpatient admission for asthma (versus 0) in the next year.
Notes: The hes subset comprised 47,718 patients (37% of the full study group). †hospital, asthma 1+, at least one asthma-related hospital attendance/admission during the 
baseline year (data from clinic records).
Abbreviations: Blood eosin, blood eosinophil count; CI, confidence interval; equiv, equivalents; FP, fluticasone propionate; GP, general practitioner; HES, Hospital Episode 
statistics; ics, inhaled corticosteroid; lrTi, lower respiratory tract infection; Ocs, oral corticosteroid.
0 µg/day
1–200
201–400
>400
1–200
201–400
401–800
>800
0.85 (0.79, 0.93)
0.89 (0.82, 0.97)
1.17 (1.08, 1.27)
0.77 (0.70, 0.84)
0.79 (0.73, 0.87)
0.99 (0.91, 1.08)
1.29 (1.19, 1.40)
<0.001
0.006
<0.001
<0.001
<0.001
0.836
<0.001
2.41.21.00.6
Average SABA dosage, µg/day
(salbutamol equivalents)
Average ICS dosage, µg/day
(FP equivalents)
Odds ratio (95% CI)
C
P-value
Odds ratios (95% CI)
Figure 2 Odds of two or more exacerbations (versus 0 or 1) in the next year.
Notes: (A) Demographic and clinical indices; (this multivariable model also includes the predictors shown in B). *Prescription for nonsteroidal anti-inflammatory drugs 
was interchangeable with acetaminophen prescription and similarly increased the likelihood of two or more exacerbations in the next year (odds ratio: 1.12 [95% ci: 1.06, 
1.18]; P,0.001). (B) Asthma treatment and control; (this multivariable model also includes the predictors shown in A). †hospital, asthma indicates asthma-related hospital 
attendance/admission (here, at least one outpatient attendance) during the baseline year. *Treatment step was interchangeable with average daily short-acting β2 agonist or 
inhaled corticosteroid dosage. (C) Average daily sABA and ics dosages when these variables replaced treatment step in the multivariable model. reference category for 
each variable is none (0 µg/day).
Abbreviations: Blood eosin, blood eosinophil count; BMI, body mass index; CI, confidence interval; FP, fluticasone propionate; GERD, gastroesophageal reflux disease; 
gP, general practitioner; ics, inhaled corticosteroid; lrTi, lower respiratory tract infection; Ocs, oral corticosteroid; sABA short-acting β2 agonist.
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recommendations,6 it is focused specifically on patients 
at risk for frequent exacerbations, and it is derived from a 
heterogeneous  population of .130,500 asthma patients. Our 
study population included teenagers and young adults, elderly 
patients, smokers, patients with significant comorbidities and 
concomitant medications, and every level of asthma severity, 
treatment intensity, and symptom control.
study limitations
Our study design was intended to be inclusive and represen-
tative of real-life asthma care, but we acknowledge that our 
study population does not perfectly represent the general 
UK asthma population. First, we excluded patients with 
other chronic respiratory diseases, such as chronic obstruc-
tive pulmonary disease (COPD). Asthma–COPD overlap 
syndrome (ACOS) reportedly occurs in 15% to 20% of 
asthma patients, and in some populations the incidence may 
be even higher.6 Patients with features of both diseases often 
experience frequent respiratory exacerbations,23 so a similar 
study is warranted in patients with both asthma and COPD. 
It is possible, perhaps even likely, that ACOS carries its own 
unique profile of exacerbation predictors.
Second, in order to determine the predictive value of blood 
eosinophil count, we excluded patients who did not have a 
numerical blood eosinophil count, so our study inevitably 
selected for asthma patients whose physicians had performed 
at least a white cell differential for some reason. It was not 
possible to determine the reasons why physicians conducted 
white blood cell counts in these patients. However, even in this 
population, only 16% of patients had systemic eosinophilia 
(.400/µL). Similar or higher rates of systemic eosinophilia 
(18% to 26%) are reported in adults with asthma,12,17,18 so our 
selection of patients with blood eosinophil counts does not 
appear to have selected particularly for patients with systemic 
eosinophilia. That said, a broader exacerbation risk study is 
nearing completion that is not limited to patients with blood 
eosinophil data and which examines the risks for multiple 
exacerbations over a 2-year outcome period in patients with 
active asthma (two or more asthma prescriptions during their 
baseline year).
Third, we did not include blood neutrophil count as an a 
priori variable, as we were focused on the predictive value 
of blood eosinophil count. In a recent study of adult-onset 
asthma, increased blood neutrophil count was associated 
with disease severity,24 so blood neutrophil count would be 
a worthwhile addition in future exacerbation risk studies of 
this type.
Lastly, ours was an observational study using historical 
data. The subtext of our hypothesis was that the modifiable 
and manageable risk factors thus identified may be targeted by 
primary-care physicians to reduce the patient’s risk of having 
multiple severe exacerbations in the next year. However, an 
interventional study using either a matched case–control or 
crossover design would be needed to show that exacerbations 
are prevented or reduced in frequency through such targeted 
interventions.
Key findings
Several of the exacerbation predictors identified in our study 
have been previously reported as significantly increasing 
the risk for frequent exacerbations. However, there are three 
findings of particular note in our study.
1. “Frequent exacerbators” are a labile, and potentially 
modifiable, group. Having even one exacerbation in the 
baseline year, as represented by acute OCS use in the full 
study group, was the single best predictor of multiple 
exacerbations in the outcome year, and the likelihood 
increased further with each additional baseline exacerba-
tion (Figure 2B). Even so, only 41% of the patients who 
had multiple exacerbations in their baseline year also had 
multiple exacerbations in the following year; the remain-
ing 59% had no exacerbations (31%) or only one (28%; 
Table S3). Thus, “frequent exacerbator” appears to be 
a more labile – and potentially more modifiable – state 
than is implied by studies aimed at characterizing it as a 
specific asthma phenotype.
2. Several novel exacerbation predictors were identified in 
routine medical records. Our study identified a number 
of novel predictors of frequent exacerbations, including 
some comorbidities and comedications not always consid-
ered in asthma management: age, increased risk per year; 
female gender; being overweight or obese (separate risks); 
comorbid diabetes (type I or II), eczema, or rhinitis; 
prescription for acetaminophen or an NSAID; antibiotic 
prescription for lower respiratory tract infection (LRTI); 
and no SABA or ICS use. When the outcome measure was 
hospitalization for asthma (Figure 3), comorbid ischemic 
heart disease was another novel exacerbation predictor.
The following factors significantly decreased the 
likelihood of multiple exacerbations: being an ex-smoker 
(versus nonsmoker); every 1% increase in percent 
predicted PEF; and low-to-moderate SABA/ICS usage 
(1–400 µg/day versus none). The apparently lower risk 
for ex-smokers may be explained by the confounding 
influences of age and acute OCS use. Ex-smokers were 
older than smokers and nonsmokers, and they had more 
acute OCS courses, so adjusting for age and acute OCS 
use in the multivariable model decreased their OR in 
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 relation to nonsmokers. More importantly, being a current 
smoker significantly increased the likelihood of multiple 
exacerbations. Average daily SABA and ICS dosages 
represent the number of refilled prescriptions in the 
year of interest (Table S1), so the lower odds of multiple 
exacerbations associated with reliever and controller use 
is also noteworthy, given that lack of adherence to asthma 
prescriptions is relatively common and it contributes to 
poor current control and increases future risk.25
Although elevated blood eosinophil count (.400/µL) 
is not a novel exacerbation predictor, it was the single 
best predictor of multiple exacerbations among all of the 
demographic and clinical indices examined. Previous 
studies suggest that systemic eosinophilia may be associ-
ated with relative resistance to ICS and thus with a greater 
need for systemic therapy, such as OCS or one of the 
monoclonal antibody therapies directed at the interleukins 
involved in eosinophil signaling.15,19–21 That may explain 
why systemic eosinophilia significantly increased the 
likelihood of multiple exacerbations, which were mostly 
represented by acute OCS use, in our study. Even though 
only 16% of the patients had systemic eosinophilia, its 
influence as a risk factor for multiple exacerbations and 
its possible association with a need for systemic therapy 
make a compelling case for the routine use of blood 
eosinophil counts in the monitoring and managing of 
patients with asthma.
3. This multivariable model enables the physician to tai-
lor exacerbation risk management for the individual 
patient. Although the exacerbation risk associated 
with most of the factors identified was relatively low, 
each contributes to a complete picture of the patient’s 
respiratory and systemic state as it relates to the risk for 
frequent exacerbations. These various predictors may be 
used by physicians to build a profile of the factors that 
contribute to an individual patient’s exacerbation risk, 
some of which are modifiable or manageable. The modifi-
able/manageable risk factors applicable to that patient, 
such as obesity, smoking habit, specific comorbidities, 
and asthma drugs or dosages, may then be targeted in the 
asthma management plan.
We are planning an algorithm that allows the physician to 
calculate the patient’s specific exacerbation risk when several 
different factors are present. In the meantime, multiplying 
the ORs of all applicable risk factors will approximate the 
patient’s risk for multiple exacerbations in the next year. 
Calculating the patient’s specific exacerbation risk in this 
way, or simply weighting all of the applicable risk factors 
in a written assessment and treatment plan, may encourage 
better self-management than general statements such as “lose 
weight”, “quit smoking”, and “use your steroid inhaler every 
day”. In support of this approach, a Cochrane Database sys-
tematic review found that written individualized management 
plans, combined with regular medical reviews, improved 
health outcomes and reduced asthma-related hospitalizations 
in adults with asthma.26
Conclusion
In this study, we aimed to identify specific predictors of fre-
quent exacerbations using data obtained solely from routine 
medical records. More than 20 different variables significantly 
increased, and in some cases decreased, the likelihood that the 
patient would experience two or more exacerbations in the next 
year. They encompassed demographic and clinical variables, 
such as age, gender, BMI, smoking status, percent predicted 
PEF, blood eosinophil count, various comorbidities, and come-
dications, as well as indices of asthma treatment and control, 
such as treatment step (alternatively, average daily SABA or 
ICS dosage), antibiotic prescription for LRTI, acute OCS use, 
and asthma-related hospital attendance/admission.
Some exacerbation risk factors are inexorable or unavoid-
able (eg, increasing age, gender), but most are either manage-
able (eg, comorbidities) or modifiable (eg, obesity, smoking). 
By identifying and quantitating all applicable risk factors, 
the physician is better equipped to formulate a treatment 
plan aimed at reducing the patient’s specific risk of frequent 
exacerbations.
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